<SEC-DOCUMENT>0001193125-24-090959.txt : 20240409
<SEC-HEADER>0001193125-24-090959.hdr.sgml : 20240409
<ACCEPTANCE-DATETIME>20240409170738
ACCESSION NUMBER:		0001193125-24-090959
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		7
FILED AS OF DATE:		20240409
DATE AS OF CHANGE:		20240409

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ventyx Biosciences, Inc.
		CENTRAL INDEX KEY:			0001851194
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				832996852
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-278584
		FILM NUMBER:		24833494

	BUSINESS ADDRESS:	
		STREET 1:		12790 EL CAMINO REAL, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 945-2393

	MAIL ADDRESS:	
		STREET 1:		12790 EL CAMINO REAL, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>d799026ds3.htm
<DESCRIPTION>S-3
<TEXT>
<HTML><HEAD>
<TITLE>S-3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on April&nbsp;9, 2024 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333-&#8195;&#8195;&#8195; </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>FORM S-3
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Ventyx Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">88-2996852</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State or other jurisdiction of <BR>incorporation or organization)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer<BR>Identification Number)</B></TD></TR></TABLE>
<P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>12790 El Camino Real, Suite 200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, CA 92130 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(760) <FONT
STYLE="white-space:nowrap">593-4832</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of
registrant&#146;s principal executive offices) </B></P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Raju Mohan,
Ph.D. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>12790 El Camino Real, Suite 200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, CA 92130 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(760) <FONT
STYLE="white-space:nowrap">593-4832</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent
for service) </B></P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Martin
J. Waters </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Robert L. Wernli, Jr. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Wilson Sonsini Goodrich&nbsp;&amp; Rosati, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Professional Corporation </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>12235 El Camino Real </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>San
Diego, CA 92130-3002 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(858) <FONT STYLE="white-space:nowrap">350-2300</FONT> </B></P>
<P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public</B>: From time to time after the effective date of the registration statement. </P>
<P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following
box:&#8194;&#9744; </P> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415
under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box:&#8194;&#9746; </P>
<P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </P> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this Form
is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&#8194;&#9744; </P> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall
become effective upon filing with the Commission pursuant to Rule&nbsp;462(e) under the Securities Act, check the following box.&#8194;&#9744; </P> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this Form
is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule&nbsp;413(b) under the Securities Act, check the
following box.&#8194;&#9744; </P> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT
STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company, or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company&#148; and
&#147;emerging growth company&#148; in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
</TABLE> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of Securities Act.&#8194;&#9744; </P> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall
thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine.
</B></P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information in this prospectus is not complete and may be changed. The securities
may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where
the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>Subject to Completion, dated April 9, 2024 </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g799026g03g03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Ventyx Biosciences, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>11,174,000 Shares of Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Offered by the Selling Stockholders </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus
covers the offer and resale from time to time of up to 11,174,000 shares of our common stock, par value $0.0001 per share, by the selling stockholders identified in this prospectus, including their transferees, pledgees or donees or their respective
successors. The shares of common stock offered by the selling stockholders consist of 11,174,000 shares that were sold and issued to the selling stockholders in a private placement pursuant to a stock purchase agreement, dated March&nbsp;6, 2024,
which closed on March&nbsp;11, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders identified in this prospectus may offer the shares of common stock pursuant
to this prospectus from time to time through public or private transactions at fixed prices, at market prices prevailing at the time of sale, at prices related to prevailing market prices or at privately negotiated prices. The selling stockholders
may sell shares to or through underwriters, broker-dealers or agents, who may receive compensation in the form of discounts, concessions or commissions from the selling stockholders, the purchasers of the shares, or both. For additional information
on the methods of sale that may be used by the selling stockholders, see the section entitled &#147;Plan of Distribution&#148; on page 13. For a list of the selling stockholders, see the section entitled &#147;Selling Stockholders&#148; on page 8.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not selling any shares of common stock under this prospectus and will not receive any proceeds from the sale by the selling
stockholders of such shares. We are paying the cost of registering the shares of common stock covered by this prospectus as well as various related expenses. The selling stockholders are responsible for all selling commissions, transfer taxes and
other costs related to the offer and sale of their shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should carefully read this prospectus and any amendments or supplements
accompanying this prospectus, together with any documents incorporated by reference herein or therein, before you make your investment decision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may sell any, all or none of the securities offered by this prospectus and we do not know when or in what amount the
selling stockholders may sell their common shares hereunder following the effective date of the registration statement of which this prospectus forms a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is currently listed on The Nasdaq Global Select Market under the symbol &#147;VTYX.&#148; On April&nbsp;3, 2024, the last
reported sale price of our common stock was $5.18 per share. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in
our securities involves risks. Please carefully read the information under the headings &#147;<A HREF="#tx799026_4">Risk Factors</A>&#148; beginning on page 4 of this prospectus as well as the &#147;Risk Factors&#148; information included in our
most recent report on Form 10-K or Form 10-Q, as applicable (under Part I, Item 1A of Form 10-K or Part II, Item 1A of Form 10-Q), which is incorporated by reference in this prospectus, before you invest in our securities. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is &#8195;&#8195;&#8195; , 2024. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B><U>Page</U></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx799026_1">About this Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx799026_2">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx799026_3">The Offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx799026_4">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx799026_5"><FONT STYLE="white-space:nowrap">Forward-Looking</FONT>
Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx799026_6">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx799026_7">Selling Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx799026_8">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx799026_9">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx799026_10">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx799026_11">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx799026_12">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx799026_13">Incorporation by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx799026_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We urge you to read carefully this prospectus, together with the information incorporated herein by reference as described under the heading
&#147;Where You Can Find More Information,&#148; before buying any of the securities being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the
information contained or incorporated by reference in this prospectus. The selling stockholders have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you
should not rely on it. This prospectus may only be used where it is legal to offer and sell shares of our common stock. If it is against the law in any jurisdiction to make an offer to sell these shares, or to solicit an offer from someone to buy
these shares, then this prospectus does not apply to any person in that jurisdiction, and no offer or solicitation is made by this prospectus to any such person. You should assume that the information appearing in this prospectus is accurate only as
of the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus or of any sale of common stock. Our business, financial condition, results of operations and prospects may have changed since such date.
Information contained on our website is not a part of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the selling stockholders have authorized any person
to provide you any information or to make any representations other than those contained in this prospectus or any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you.
Neither we nor the selling stockholders take responsibility for, and can provide assurance as to the reliability of, any other information that others may give you. Neither we nor the selling stockholders are making an offer to sell these securities
in any jurisdiction where the offer or sale is not permitted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities and Exchange Commission (the &#147;SEC&#148;) using the &#147;shelf&#148; registration process. Under this shelf registration process, the selling stockholders hereunder may,
from time to time, issue, offer and sell, as applicable, any combination of the securities described in this prospectus in one or more offerings. The selling stockholders may use this prospectus to sell up to an aggregate of 11,174,000 shares of
common stock from time to time through any means described in the section entitled &#147;Plan of Distribution.&#148; We will not receive any proceeds from the sale by such selling stockholders of the securities offered by them described in this
prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also provide a prospectus supplement or post-effective amendment to the registration statement to add information to,
or update or change information contained in, this prospectus. Before purchasing any securities, you should read both this prospectus and any applicable prospectus supplement or post-effective amendment to the registration statement together with
the additional information to which we refer you in the section of this prospectus titled &#147;Where You Can Find More Information.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information contained in this prospectus concerning the market and the industry in which we compete, including our market position, general
expectations of market opportunity and market size, is based on information from various third-party sources, on assumptions made by us based on such sources and our knowledge of the markets for our services and solutions. Any estimates provided
herein involve numerous assumptions and limitations, and you are cautioned not to give undue weight to such information. Third-party sources generally state that the information contained in such source has been obtained from sources believed to be
reliable; however, we have not verified the accuracy or completeness of third-party data. The industry in which we operate is subject to a high degree of uncertainty and risk. As a result, the estimates and market and industry information provided
in this prospectus are subject to change based on various factors, including those described in the risk factors incorporated herein in the sections entitled &#147;Risk Factors-Risks Related to Our Business and Risks Related to Our Common
Stock&#148; and elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx799026_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information that is presented in greater detail elsewhere, or incorporated by reference, in this
prospectus. It does not contain all of the information that may be important to you and your investment decision. Before investing in our securities, you should carefully read this entire prospectus, including the matters set forth in the section
titled &#147;Risk Factors&#148; and the financial statements and related notes and other information that we incorporate by reference herein, including our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and our Quarterly Reports
on Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> Unless the context indicates otherwise, references in this prospectus to &#147;Ventyx Biosciences, Inc.,&#148; &#147;we,&#148; &#147;our&#148; and &#147;us&#148; refer, collectively, to Ventyx
Biosciences, Inc., a Delaware corporation, and its subsidiaries taken as a whole. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company developing a pipeline of novel small molecule product candidates to address a range of
inflammatory diseases with significant unmet need. We leverage the substantial experience of our team in immunology to identify important new targets and to develop differentiated therapeutics against these targets. Our clinical product candidates
address therapeutic indications with substantial commercial opportunity for novel small molecules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2024, we
completed a Phase 1 trial in healthy volunteers of VTX3232, our novel <FONT STYLE="white-space:nowrap">CNS-penetrant</FONT> peripheral-targeted <FONT STYLE="white-space:nowrap">NOD-like</FONT> receptor protein 3 (NLRP3) inflammasome inhibitor.
VTX3232 was well-tolerated with no dose-limiting toxicities identified. We expect to initiate a Phase 2a trial of VTX3232 in patients with early Parkinson&#146;s disease during the second half of 2024. We also expect to initiate a Phase 2a trial of
VTX3232 in subjects with obesity and certain additional risk factors for cardiovascular disease during the second half of 2024. In addition, in the first quarter of 2024, we announced positive results from a Phase 2 trial for VTX2735, our novel
peripheral NLRP3 inhibitor, in cryopyrin-associated periodic syndrome (CAPS) patients. We plan to evaluate VTX2735 in cardiovascular diseases with an initial focus on the secondary prevention of major adverse cardiovascular events (MACE) and
recurrent pericarditis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we are conducting a Phase 2 trial of VTX958, a selective allosteric tyrosine kinase type 2 (TYK2)
inhibitor, in moderately to severely active Crohn&#146;s disease, for which we expect to report topline results in the middle of 2024. Finally, we are developing VTX002, a sphingosine 1 phosphate receptor (S1P1R) modulator for the treatment of
moderately to severely active ulcerative colitis (UC). In the fourth quarter of 2023, we announced positive results from the Phase 2 trial of VTX002 in patients with moderately to severely active UC. Activities are underway to prepare for a Phase 3
trial of VTX002 in UC. We intend to identify a partner or other source of <FONT STYLE="white-space:nowrap">non-dilutive</FONT> financing to support the pivotal Phase 3 trial of VTX002 in UC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were
incorporated in Delaware on November&nbsp;21, 2018. Until February 2021, we focused primarily on developing our product candidate, VTX958, which we acquired from Vimalan Biosciences. In February 2021, we acquired all of the issued and outstanding
equity of each of Oppilan Pharma Ltd. (&#147;Oppilan&#148;), including its lead candidate VTX002, and Zomagen Biosciences Ltd. (&#147;Zomagen&#148;), including its lead candidate VTX2735, and following such acquisitions, each of Oppilan and Zomagen
became our wholly owned subsidiaries. Although we acquired these product candidates, each candidate was developed by one or more members of our management team. Our principal executive offices are located at 12790 El Camino Real, Suite 200, San
Diego, CA 92130. Our telephone number is <FONT STYLE="white-space:nowrap">(760)&nbsp;593-4832.&nbsp;Our</FONT> website address is http://www.ventyxbio.com. Information contained on, or that can be accessed through, the website is not incorporated by
reference into this prospectus and the inclusion of our website address in this prospectus is an inactive textual reference only. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use
Ventyx, the Ventyx logo and other marks as trademarks in the United States and other countries. This prospectus contains references to our trademarks and service marks and to those belonging to other entities.
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork and other visual displays, may appear without the&nbsp;<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;or&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>&nbsp;symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent
under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#146; trade names, trademarks or service marks to imply a relationship with, or
endorsement or sponsorship of us by, any other entity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placement and Stock Purchase Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;6, 2024, we entered into a stock purchase agreement for a private placement with certain qualified institutional buyers and
institutional accredited investors. Pursuant to the stock purchase agreement, we agreed to sell to the purchasers 11,174,000 shares of our common stock, par value $0.0001 per share, at an offering price of $8.95 per share. The gross proceeds of the
private placement were approximately $100.0&nbsp;million, before deducting placement agent fees and other expenses. The private placement closed on March&nbsp;11, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the private placement, we entered into a registration rights agreement with the purchasers, dated March&nbsp;6, 2024,
providing for the registration of the offer and resale of the shares that are not then registered on an effective registration statement, pursuant to a registration statement to be filed with the SEC on or prior to April&nbsp;10, 2024 (30 days after
the closing of the private placement). We have agreed to keep such registration statement continuously effective from the date on which the SEC declares the registration statement to be effective until such date that all registrable securities (as
defined in the registration rights agreement) covered by the registration statement have been sold pursuant to a registration statement under the&nbsp;Securities Act&nbsp;or under Rule 144 as promulgated by the SEC under the&nbsp;Securities Act.
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx799026_3"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by selling stockholders </P></TD>
<TD>11,174,000 shares. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Offering Price </P></TD>
<TD>The selling stockholders may sell all or a portion of their shares through public or private transactions at prevailing market prices or at privately negotiated prices. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We will not receive any proceeds from the sale of shares of common stock by the selling stockholders. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>See the section titled &#147;Risk Factors&#148; included in, and the risk factors incorporated by reference in this prospectus, for a discussion of factors you should carefully consider before deciding to invest in shares of our common stock.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq trading symbol </P></TD>
<TD>&#147;VTYX&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders named in this prospectus may offer and sell up to 11,174,000 shares of our
common stock. Throughout this prospectus, when we refer to the shares of our common stock being registered on behalf of the selling stockholders for offer and resale, we are referring to the shares of common stock issued to the selling stockholders
in the private placement, respectively, as described above. When we refer to the selling stockholders in this prospectus, we are referring to the selling stockholders identified in this prospectus and, as applicable, their permitted transferees or
other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> that may be identified in a supplement to this prospectus or, if required, a post-effective amendment to the registration statement of which
this prospectus is a part. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx799026_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, and
the risk factors set forth under &#147;Risk Factors&#148; in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and subsequently filed Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> which are incorporated
by reference in this prospectus, together with all other information included or incorporated by reference in this prospectus, as updated by our subsequent filings under the Securities and Exchange Act of 1934 (the &#147;Exchange Act&#148;), and the
risk factors and other information contained in any applicable prospectus supplement, before making an investment decision. The risks and uncertainties described below may not be the only ones we face. If any of the risks actually occur, our
business, financial condition, operating results, cash flows and prospects could be materially and adversely affected. In that event, the market price of our common stock could decline, and you could lose part or all of your investment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to This Offering. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The number of shares being registered for sale is significant in relation to the number of outstanding shares of our Common Stock.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed a registration statement of which this prospectus is a part to register the shares offered hereunder for sale into
the public market by the selling stockholders. Upon registration of the shares of common stock offered hereunder, 11,174,000 shares of the common stock registered hereunder may be resold in the public market immediately without restriction. These
shares represent a large number of shares of our common stock, and if sold in the market all at once or at about the same time, could depress the market price of our common stock during the period the registration statement remains effective and
could also affect our ability to raise equity capital. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx799026_5"></A><FONT STYLE="white-space:nowrap">FORWARD-LOOKING</FONT>
STATEMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, any applicable prospectus supplement or free writing prospectus and our SEC filings that are incorporated
by reference into this prospectus and any applicable prospectus supplement or free writing prospectus contain or incorporate by reference forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act, Section&nbsp;21E of
the&nbsp;Exchange Act&nbsp;and the Private Securities Litigation Reform Act of 1995, and such statements are subject to the &#147;safe harbor&#148; created by those sections. In some cases, you can identify forward-looking statements by the
following words: &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;ongoing,&#148; &#147;plan,&#148; &#147;potential,&#148;
&#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would&#148; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements involve risks, uncertainties and other factors that may cause our actual results, levels of activity,
performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this
prospectus, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this prospectus include, but
are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding our product candidates and their related benefits; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated timing of releasing data for any current or future clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated timing of commencement, enrollment, and completion of any current or future clinical trials for
our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing or likelihood of regulatory filings or other actions and related regulatory authority responses;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our beliefs regarding the perceived benefits and limitations of competing products, and the future of competing
products and our industry; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">details regarding our strategic vision and product candidate pipeline; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our beliefs regarding the success, cost and timing of our development activities and current and future clinical
trials, including study design; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruptions in the supply chain, including raw materials needed for manufacturing, animals used in research,
delays in site activations and enrollment of clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any impact of the military conflicts in Ukraine or the Middle East or the imposition of sanctions against certain
countries as a result thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability and willingness of third parties to engage in research and development activities on our behalf
involving our product candidates, and our ability to leverage those activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the ease of administration associated with our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the patient compatibility associated with our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our beliefs regarding the potential markets for our product candidates and our ability to serve those markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to obtain and maintain regulatory approval of any of our product candidates, and any related
restrictions, limitations and/or warnings in the label of any approved product candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to commercialize any approved products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance of approved products, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key personnel; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the accuracy of our estimates regarding our future revenue, operating expenses, capital requirements and needs
for additional financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sufficiency of our existing cash, cash equivalents and marketable securities to fund our future operating
expenses and capital expenditure requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain funding for our operations, including funding necessary to complete further development and
any commercialization of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain, maintain, protect and enforce intellectual property protection for our product candidates
and not infringe, misappropriate or otherwise violate the intellectual property of others; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States and foreign countries. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties
that affect our business described in the &#147;Risk Factors&#148; section, our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K,&nbsp;Quarterly</FONT> Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q,&nbsp;Current</FONT>
Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;and</FONT> other documents filed by us from time to time with the SEC. See &#147;Where You Can Find More Information&#148; beginning on page 17 of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. These
statements are based upon information available to us as of the date of this prospectus, and although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should
not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant
uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We undertake no
obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx799026_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the shares of common stock offered by the selling stockholders pursuant to this prospectus will be sold by the selling stockholders for
their respective accounts. We will not receive any of the proceeds from these sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders will pay any underwriting
discounts and commissions and expenses incurred by them for brokerage, accounting, tax or legal services or any other expenses incurred in disposing of the securities. We will bear the costs, fees and expenses incurred in effecting the registration
of the shares covered by this prospectus, including all registration and filing fees, Nasdaq listing fees and fees and expenses of our counsel and our independent registered public accounting firm. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx799026_7"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus covers the offer and resale or other disposition of up to 11,174,000 shares of our common stock by the selling stockholders
named below, and their donees, pledgees, transferees or&nbsp;other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> selling&nbsp;shares of common stock or interests in shares of common stock
received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer. These shares consist of 11,174,000 shares of common stock that were issued to the selling stockholders in the
private placement. See &#147;Prospectus Summary&#151; Private Placement and Stock Purchase Agreement.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below sets forth,
to our knowledge, information concerning the beneficial ownership of shares of our common stock by the selling stockholders as of March&nbsp;11, 2024. The information in the table below with respect to the selling stockholders has been obtained from
the respective selling stockholders. The selling stockholders may sell all, some or none of the shares of common stock subject to this prospectus. See &#147;Plan of Distribution&#148; as may be supplemented and amended from time to time. We do not
know how long the selling stockholders will hold the shares before selling them, and we currently have no agreements, arrangements or understandings with the selling stockholders regarding the sale or other disposition of any of the shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of common stock beneficially owned prior to the offering for each selling stockholder includes (i)&nbsp;all shares of our
common stock beneficially held by such selling stockholder as of March&nbsp;11, 2024, (ii) the number of shares of our common stock that may be offered under this prospectus, and (iii)&nbsp;the number and percentage of our common stock beneficially
owned by the selling stockholders assuming all of the shares of our common stock registered hereunder are sold. The table below and footnotes assume that the selling stockholders will sell all of the shares listed. However, because the selling
stockholders may sell all or some of their shares under this prospectus from time to time, or in another permitted manner, we cannot assure you as to the actual number of shares that will be sold by the selling stockholders or that will be held by
the selling stockholders after completion of any sales. The percentages of shares owned after the offering are based on 70,499,201 shares of common stock outstanding as of April&nbsp;3, 2024, which includes the outstanding shares of common stock
offered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment
power with respect to our common stock. Generally, a person &#147;beneficially owns&#148; shares of our common stock if the person has or shares with others the right to vote those shares or to dispose of them, or if the person has the right to
acquire voting or disposition rights within 60 days. The inclusion of any shares in this table does not constitute an admission of beneficial ownership for any selling stockholder named below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information about the selling stockholders may change over time. Any changed information
will be set forth in an amendment to the registration statement or supplement to this prospectus, to the extent required by law. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Common<BR>Stock Beneficially<BR>Owned Prior to Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of<BR>Common&nbsp;Stock<BR>Being&nbsp;Offered<SUP STYLE="font-size:75%; vertical-align:top">&nbsp;(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of Common<BR>Stock to be<BR>Beneficially Owned<BR>After Offering <SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Selling Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Farallon Capital Management, L.L.C. (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,167,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,790,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">377,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Redmile Group, LLC&nbsp;(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,177,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cormorant Global Healthcare Master Fund, LP&nbsp;(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,420,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,420,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citadel CEMF Investments Ltd. (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,178,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,178,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Octagon Investments Master Fund LP&nbsp;(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,391,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">890,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,501,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Point72 Associates, LLC&nbsp;(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,190,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">838,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,352,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deerfield Partners, L.P. (9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,296,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">838,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,458,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Columbia Management Investment Advisers, LLC&nbsp;(10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">220,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">220,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indicates beneficial ownership of less than 1% of the total outstanding common stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of shares of our common stock in the column &#147;Number of Shares of Common Stock Being
Offered&#148; represents all of the shares of our common stock that a selling stockholder may offer and sell from time to time under this prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We do not know when or in what amounts a selling stockholder may offer shares for sale. The selling
stockholders might not sell any or might sell all of the shares offered by this prospectus. Because the selling stockholders may offer all or some of the shares pursuant to this offering, and because, except as set forth elsewhere in this
prospectus, there are currently no agreements, arrangements or understandings with respect to the sale of any of the shares, we cannot estimate the number of the shares that will be held by the selling stockholders after completion of the offering.
However, for purposes of this table, we have assumed that, after completion of the offering, none of the shares covered by this prospectus will be held by the selling stockholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The 2,790,000 shares that are the subject of this resale registration statement are held directly by the
Farallon Funds (as defined below), as follows: (i)&nbsp;Farallon Capital Partners, L.P. (&#147;<B>FCP</B>&#148;) holds 560,511 shares; (ii)&nbsp;Farallon Capital Institutional Partners, L.P. (&#147;<B>FCIP</B>&#148;) holds 496,899 shares; (iii)
Farallon Capital Institutional Partners II, L.P. (&#147;<B>FCIP II</B>&#148;) holds 108,252 shares; (iv)&nbsp;Four Crossings Institutional Partners V, L.P. (&#147;<B>FCIP V</B>&#148;) holds 80,352 shares; (v)&nbsp;Farallon Capital Offshore Investors
II, L.P. (&#147;<B>FCOI II</B>&#148;) holds 1,170,684 shares; (vi)&nbsp;Farallon Capital (AM) Investors, L.P. (&#147;<B>FCAMI</B>&#148;) holds 62,496 shares; and (vii)&nbsp;Farallon Capital F5 Master I, L.P. (&#147;<B>F5 MI</B>&#148; and, together
with the entities listed in (i)&nbsp;to (v)&nbsp;(vi) above, the &#147;<B>Farallon</B> <B>Funds</B>&#148;) holds 310,806 shares. Farallon Partners, L.LC., a Delaware limited liability company (the &#147;<B>Farallon General Partner</B>&#148;), as the
general partner of each of FCP, FCIP, FCIP II, FCOI II and FCAMI, may be deemed a beneficial owner of the shares held by FCP, FCIP, FCIP II, FCOI II and FCAMI. Farallon Institutional (GP) V, L.L.C., a Delaware limited liability company (the
&#147;<B>FCIP V General Partner</B>&#148;), as the general partner of FCIP V, may be deemed a beneficial owner of the shares held by FCIP V. Farallon F5 (GP), L.L.C. (the &#147;<B>F5 General Partner</B>&#148;), a Delaware limited liability company,
as the general partner of F5 MI, may be deemed a beneficial owner of the shares held by F5 MI. Each of Joshua J. Dapice, Philip D. Dreyfuss, Hannah E. Dunn, Richard B. Fried, Varun N. Gehani, Nicolas Giauque, David T. Kim, Michael G. Linn, Rajiv A.
Patel, Thomas G. Roberts, Jr., Edric C. Saito, William Seybold, Daniel S. Short, Andrew J. M. Spokes, John R. Warren and Mark C. Wehrly (collectively, the &#147;<B>Farallon Managing Members</B>&#148;), as a senior managing member or managing member,
as the case may be, of the Farallon General Partner, and a manager or senior manager, as the case may be, of the FCIP V General Partner and the F5 General Partner, in each case with the power to exercise investment discretion, may be
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
deemed a beneficial owner of all such shares held by the Farallon Funds. Each of the Farallon General Partner, the FCIP V General Partner, the F5 General Partner, and the Farallon Managing
Members hereby disclaims any beneficial ownership of such shares. The address of each of the entities and individuals referenced in this note is c/o Farallon Capital Management, L.L.C., One Maritime Plaza, Suite 2100, San Francisco, CA 94111.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The 2,000,000 shares of common stock that are the subject of this resale registration statement consist of the
following: (i) 38,541 shares of common stock held directly by Map 20 Segregated Portfolio, a segregated portfolio of LMA SPC, (ii) 294,191 shares of common stock held directly by Redmile Capital Fund, LP, (iii) 287,631 shares of common stock held
directly by Redmile Capital Offshore Master Fund, Ltd., (iv) 977,900 shares of common stock held directly by Redmile Strategic Long Only Trading Sub, Ltd., and (v) 401,737 shares of common stock held directly by Redmile Strategic Trading Sub, Ltd.
(collectively, the entities listed in (i)&nbsp;to (v) above, the &#147;<B>Redmile Funds</B>&#148;). Redmile Group, LLC (&#147;<B>Redmile</B>&#148;) is the investment manager/adviser to the Redmile Funds and, in such capacity, exercises voting and
investment power over all of the shares held by the Redmile Funds and may be deemed to be the beneficial owner of these shares of common stock. Jeremy C. Green serves as the managing member of Redmile and may be deemed to be the beneficial owner of
these shares. Redmile and Mr.&nbsp;Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. The address of the Redmile Funds is c/o Redmile Group, LLC, One Letterman
Drive, Suite <FONT STYLE="white-space:nowrap">D3-300,</FONT> San Francisco, CA 94129. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The 1,420,000 shares of common stock that are the subject of this resale registration statement are held by
Cormorant Global Healthcare Master Fund, LP (the &#147;<B>Cormorant Master Fund</B>&#148;). Cormorant Global Healthcare GP, LLC (&#147;<B>Global GP</B>&#148;) serves as the general partner of Cormorant Master Fund. Cormorant Asset Management, LP
serves as the investment manager to Cormorant Master Fund. Bihua Chen serves as the managing member of Global GP and Cormorant Asset Management, LP. Each of Global GP, Cormorant Asset Management, LP and Ms.&nbsp;Chen disclaims beneficial ownership
of such shares except to the extent of any pecuniary interest therein. The principal address for the entities/individuals listed above is 200 Clarendon Street 52nd Floor, Boston, Massachusetts 02116. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The 2,178,000 shares of common that are the subject of this resale registration statement are held by Citadel
CEMF Investments Ltd. Citadel Advisors LLC is the portfolio manager of Citadel CEMF Investments Ltd. Citadel Advisors Holdings LP (&#147;<B>CAH</B>&#148;) is the sole member of Citadel Advisors LLC. Citadel GP LLC (&#147;<B>CGP</B>&#148;) is the
general partner of CAH. Kenneth Griffin owns a controlling interest in CGP. Mr.&nbsp;Griffin, as the owner of a controlling interest in CGP, may be deemed to have shared power to vote or direct the vote of, and/or shared power to dispose or to
direct the disposition over, the shares covered by this registration statement. This disclosure is not and shall not be construed as an admission that Mr.&nbsp;Griffin or any of the Citadel related entities listed above is the beneficial owner of
any securities of the Company other than the securities actually owned by such person (if any). The address of Citadel CEMF Investments Ltd. is c/o Citadel Enterprise Americas, Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, FL
33131. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The 890,000 shares of common that are the subject of this resale registration statement are held by Octagon
Investments Master Fund LP. Octagon Capital Advisors LP is the investment manager of Octagon Investments Master Fund LP. Ting Jia, Ph.D. is the founder, managing member and chief investment officer of Octagon Capital Advisors LP. By virtue of such
relationships, Dr.&nbsp;Jia and Octagon Capital Advisors LP may be deemed to have voting and investment power of the shares held by Octagon Investments Master Fund LP. Each of Dr.&nbsp;Jia and Octagon Capital Advisors LP disclaims beneficial
ownership of the shares held by Octagon Investments Master Fund LP, except to the extent of his or its pecuniary interest therein, if any. The address for each of Dr.&nbsp;Jia, Octagon Capital Advisors and Octagon Investments Master Fund LP is 654
Madison Avenue, 21st Floor, New York, NY 10065. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The 838,000 shares of common that are the subject of this resale registration statement are held by Point72
Associates, LLC (the &#147;<B>Point72 Associates</B>&#148;). Pursuant to an investment management agreement, Point72 Asset Management, L.P. (&#147;<B>Point72 Asset Management</B>&#148;) maintains investment and voting power with respect to the
securities held by certain investment funds it manages, including Point72 Associates. Point72 Capital Advisors, Inc. is the general partner of Point72 Asset Management, L.P. Mr.&nbsp;Steven&nbsp;A. Cohen controls each of Point72 Asset Management,
L.P. and Point72 Capital Advisors, Inc. By reason of the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
provisions of Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Exchange Act, each of Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Mr.&nbsp;Cohen may be deemed to
beneficially own the securities held by Point72 Associates reflected herein. Each of Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Mr.&nbsp;Cohen disclaims beneficial ownership of any such securities. The address for Point72
Associates is c/o Point72 Asset Management, 72 Cummings Point Road, Stamford, CT 06902. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The general partner of Deerfield Partners, L.P. is Deerfield Mgmt, L.P. Deerfield Management Company, L.P. is
the investment manager of Deerfield Partners, L.P. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt, L.P. and Deerfield Management Company, L.P. Each of Deerfield Management Company, L.P., Deerfield Mgmt, L.P. and
Mr.&nbsp;Flynn may be deemed to beneficially own the securities held by Deerfield Partners, L.P. The principal business address of Deerfield Partners, L.P. is 345 Park Avenue South, 12th Floor, New York, NY 10010. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The 220,000 shares of common that are the subject of this resale registration statement consist of the
following: (i) 107,096 shares of common stock held directly by Seligman Tech Spectrum Offshore Fund (Columbia) (the &#147;<B>STS Offshore Fund</B>&#148;), and (ii) 112,904 shares of common stock held directly by Seligman Tech Spectrum (Master) Fund
(the &#147;<B>STS Master Fund</B>&#148;). Columbia Management Investment Advisers, LLC serves as investment manager to the STS Offshore Fund and STS Master Fund. Paul Wick, the portfolio manager of the STS Offshore Fund and STS Master Fund, may be
deemed to have voting and investment control over the common stock held by the STS Offshore Fund and STS Master Fund. The business address of STS Offshore Fund, STS Master Fund, Columbia Management Investment Advisers, LLC and Paul Wick is 290
Congress Street, Boston, MA 02210. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx799026_8"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The description of our capital stock is incorporated by reference to Exhibit&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/1851194/000095017022004442/vtyx-ex4_3.htm">4.3</A> to our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the fiscal year ended December&nbsp;
31, 2023, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1851194/000095017024021160/vtyx-20231231.htm">February<U></U>&nbsp;27, 2024</A>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx799026_9"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders, which as used herein includes donees, pledgees, transferees or other <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> selling shares of common stock or interests in shares of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution
or other transfer, may, from time to time, sell, transfer, distribute in kind for no consideration or otherwise dispose of any or all of their shares of common stock or interests in shares of common stock on any stock exchange, market or trading
facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the
time of sale, or at negotiated prices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may use any one or more of the following methods when disposing of shares
or interests therein: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a
portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">short sales effected after the date the registration statement of which this prospectus is a part is declared
effective by the SEC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange
or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated
price per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distributions to members, partners, stockholders or other equityholders of the selling stockholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale or distribution; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted by applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by
them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule
424(b)(3) or other applicable provision of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders
under this prospectus. The selling stockholders also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> will be the selling stockholders for purposes of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the sale of our common stock or interests therein, the selling stockholders may enter into hedging transactions with
broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholders may also sell shares of our common stock short and deliver these
securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions with broker-dealers or other
financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial
institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Broker-dealers engaged by the selling stockholders may arrange for other broker-dealers to
participate in sales. Broker-dealers may receive commissions in the form of discounts, concessions or commissions from the selling stockholders or commissions from purchasers of the shares of common stock for whom they may act as agent or to whom
they may sell as principal. Such commissions will be in amounts to be negotiated, but, except as set forth in a further prospectus supplement or an amendment to this prospectus, in the case of an agency transaction not in excess of a customary
brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction, a markup or markdown in compliance with FINRA Rule 2121.01 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common
stock less discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly
or through agents. We will not receive any of the proceeds from this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders also may resell all or a portion
of the shares in open market transactions in reliance upon Rule 144 under the Securities Act,&nbsp;<U>provided</U>&nbsp;that they meet the criteria and conform to the requirements of that rule, or another available exemption from the registration
requirements of the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders and any underwriters, broker-dealers or agents that participate in the sale
of the common stock or interests therein may be &#147;underwriters&#148; within the meaning of Section&nbsp;2(a)(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of the shares may be underwriting
discounts and commissions under the Securities Act. Selling stockholders who are &#147;underwriters&#148; within the meaning of Section&nbsp;2(a)(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities
Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent required, the shares of our common stock to be sold, the names of the selling stockholders, the respective purchase
prices and public offering prices, the names of any agents, dealer or underwriter, and any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a
post-effective amendment to the registration statement that includes this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to comply with the securities laws of some
states, if applicable, the common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified for sale or an
exemption from registration or qualification requirements is available and is complied with. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have advised the selling stockholders
that the anti-manipulation rules of Regulation M under the Securities Exchange Act of 1934, as amended, may apply to sales of shares in the market and to the activities of the selling stockholders and their affiliates. In addition, to the extent
applicable, we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling
stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the selling stockholders against liabilities, including liabilities under the Securities Act and state securities
laws, relating to the registration of the shares offered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed with the selling stockholders to use
commercially reasonable efforts to cause the registration statement of which this prospectus constitutes a part to become effective and to remain continuously effective until the earlier of (1)&nbsp;such time as all of the shares covered by this
prospectus have been disposed of pursuant to and in accordance with such registration statement or (2)&nbsp;the date that all the shares covered by this prospectus cease to be Registrable Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx799026_10"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the shares of the common stock offered in this prospectus will be passed upon for us by Wilson Sonsini Goodrich&nbsp;&amp;
Rosati, Professional Corporation, San Diego, California. Certain members of, and investment partnerships comprised of members of, and person associated with, Wilson Sonsini Goodrich&nbsp;&amp; Rosati, Professional Corporation, directly or indirectly
own less than 0.1% of the outstanding shares of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx799026_11"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Ventyx Biosciences, Inc. appearing in Ventyx Biosciences, Inc.&#146;s Annual Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;for</FONT> the year ended December&nbsp;31, 2023, and the effectiveness of Ventyx Biosciences, Inc.&#146;s internal control over financial reporting as of December&nbsp;31, 2023, have been audited by
Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in
reliance upon such reports given on the&nbsp;authority of such firm as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx799026_12"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the
public over the Internet at the SEC&#146;s website at<I>&nbsp;http://www.sec.gov</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We make available, free of charge, through our
investor relations website, our Annual Reports on&nbsp;Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly&nbsp;Reports on&nbsp;Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current&nbsp;Reports on&nbsp;Form <FONT
STYLE="white-space:nowrap">8-K,</FONT> statements&nbsp;of changes in beneficial ownership of securities and amendments to those reports and statements as soon as reasonably practicable after they are filed with the SEC. The address for our website
is<I>&nbsp;http://www.ventyxbio.com</I>. The contents on our website are not part of this prospectus, and the reference to our website does not constitute incorporation by reference into this prospectus of the information contained at that site.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement we filed with the SEC. This prospectus omits some information contained in the
registration statement in accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information about us and our consolidated subsidiaries and our securities. Statements in
this prospectus concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings. You should review the complete
document to evaluate these statements. You can obtain a copy of the registration statement from the SEC&#146;s website. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx799026_13"></A>INCORPORATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; into this prospectus the information we file with the SEC. This means that we can
disclose important information to you by referring you to those documents. Any statement contained in a document incorporated by reference in this prospectus shall be deemed to be modified or superseded for purposes of this prospectus to the extent
that a statement contained herein, or in any subsequently filed document, which also is incorporated by reference herein, modifies or supersedes such earlier statement. Any such statement so modified or superseded shall not be deemed, except as so
modified or superseded, to constitute a part of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby incorporate by reference into this prospectus the following
documents that we have filed with the SEC under the&nbsp;Securities Act&nbsp;and under the&nbsp;Exchange Act&nbsp;(other than current reports on&nbsp;Form <FONT STYLE="white-space:nowrap">8-K,</FONT> or&nbsp;portions thereof, furnished under Items
2.02 or 7.01 of&nbsp;Form <FONT STYLE="white-space:nowrap">8-K):</FONT> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023,
filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1851194/000095017024021160/vtyx-20231231.htm">February<U></U>&nbsp;27, 2024</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sections of our definitive proxy statement on Schedule 14A&nbsp;for the 2023 Annual Meeting of Stockholders,
filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1851194/000119312523118542/d641116ddef14a.htm">April<U></U>&nbsp;26, 2023</A>, that are incorporated by reference in our Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;
31, 2022, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1851194/000095017023009501/vtyx-20221231.htm">March&nbsp;23, 2023</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1851194/000119312524061538/d765460d8k.htm">March
<U></U>&nbsp;7, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1851194/000119312524064405/d737752d8k.htm">March<U></U>&nbsp;
11, 2024</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1851194/000119312524088624/d772548d8k.htm">April&nbsp;5, 2024</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in<A HREF="http://www.sec.gov/Archives/edgar/data/1851194/000095017022004442/vtyx-ex4_3.htm">&nbsp;Exhibit
 4.3</A>&nbsp;to our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;filed</FONT> with the SEC on March&nbsp;24, 2022, including any amendment or report updating such description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All documents that we file with the SEC pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act (other than current reports on
Form <FONT STYLE="white-space:nowrap">8-K,</FONT> or portions thereof, furnished under Items 2.02 or 7.01 of Form <FONT STYLE="white-space:nowrap">8-K)&nbsp;(i)</FONT> after the initial filing date of the registration statement of which this
prospectus forms a part and prior to the effectiveness of such registration statement and (ii)&nbsp;after the date of this prospectus and prior to the termination of the offering shall be deemed to be incorporated by reference in this prospectus
from the date of filing of the documents, unless we specifically provide otherwise. Information that we file with the SEC will automatically update and may replace information previously filed with the SEC. To the extent that any information
contained in any current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or any exhibit thereto, was or is furnished to, rather than filed with the SEC, such information or exhibit is specifically not incorporated by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon written or oral request made to us at the address or telephone number below, we will, at no cost to the requester, provide to each
person, including any beneficial owner, to whom this prospectus is delivered, a copy of any or all of the information that has been incorporated by reference in this prospectus (other than an exhibit to a filing, unless that exhibit is specifically
incorporated by reference into that filing), but not delivered with this prospectus. You may also access this information on our website at https://www.ventyxbio.com by viewing the &#147;SEC Filings&#148; subsection of the &#147;Investors&nbsp;&amp;
News&#148; menu. No additional information on our website is deemed to be part of or incorporated by reference into this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ventyx Biosciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12790 El
Camino Real, Suite 200 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">San Diego, CA 92130 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(760) <FONT
STYLE="white-space:nowrap">593-4832</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&#8201;14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Expenses of Issuance and Distribution </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the expenses incurred or expected to be incurred in connection with the offering described in this registration
statement and the private placement, other than placement agent fees, all of which will be paid by us. All amounts are estimates except the Securities and Exchange Commission&#146;s registration fee. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount<BR>to&nbsp;be&nbsp;Paid</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee for securities offered by the selling stockholders identified in the
prospectus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">288,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&#8201;15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification of Directors and Officers </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the Delaware General Corporation Law authorizes a corporation&#146;s board of directors to grant, and authorizes a court to
award, indemnity to officers, directors and other corporate agents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation contains provisions that limit the
liability of our directors and certain of our officers for monetary damages to the fullest extent permitted by the Delaware General Corporation Law. Consequently, our directors will not be personally liable to us or our stockholders for monetary
damages for any breach of fiduciary duties as directors, except liability for the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of their duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of
the Delaware General Corporation Law; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which they derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, our officers who at the time of an act or omission as to which liability is asserted consented to or are deemed to have consented
to certain service of process rules under Delaware law will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as officers, except for liability in connection with: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of their duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which they derived an improper personal benefit; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action by or in the right of the corporation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any amendment, repeal or elimination of these provisions will not eliminate or reduce the effect of these provisions in respect of any act,
omission or claim that occurred or arose prior to that amendment, repeal or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
elimination. If the Delaware General Corporation Law is amended to provide for further limitations on the personal liability of directors or officers of corporations, then the personal liability
of our directors and officers will be further limited to the greatest extent permitted by the Delaware General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, our bylaws provide that we will indemnify our directors and officers, and may indemnify our employees, agents and any other persons, to the fullest extent permitted by the Delaware General Corporation Law. Our bylaws also provide that we
must advance expenses incurred by or on behalf of a director or officer in advance of the final disposition of any action or proceeding, subject to limited exceptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, we have entered into indemnification agreements with each of our directors and executive officers that may be broader than the
specific indemnification provisions contained in the Delaware General Corporation Law. These indemnification agreements require us to, among other things, indemnify our directors and executive officers against liabilities that may arise by reason of
their status or service. These indemnification agreements also generally require us to advance all expenses reasonably and actually incurred by our directors and executive officers in investigating or defending any such action, suit or proceeding.
We believe that these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in our certificate of incorporation, bylaws and indemnification agreements may
discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if
successful, might benefit us and other stockholders. Further, a stockholder&#146;s investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against our directors and officers as required by these
indemnification provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have obtained insurance policies under which, subject to the limitations of the policies, coverage is
provided to our directors and officers against loss arising from claims made by reason of breach of fiduciary duty or other wrongful acts as a director or officer, including claims relating to public securities matters, and to us with respect to
payments that may be made by us to our directors and officers pursuant to our indemnification obligations or otherwise as a matter of law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors may, through their relationships with their employers, be
insured or indemnified against certain liabilities incurred in their capacity as members of our board of directors. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&#8201;16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exhibits </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Incorporation by Reference</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Form</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>File</B><br><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B><br><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Filing</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Filed</B><br><B>Herewith</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1851194/000095017023041347/vtyx-ex3_1.htm">Amended and Restated Certificate of Incorporation, as amended June&nbsp;9, 2023 </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">10-Q</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">001-40928</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8/10/2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1851194/000119312522302831/d606553dex31.htm">Amended and Restated Bylaws </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">001-40928</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">12/12/2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1851194/000119312521299315/d160345dex42.htm">Specimen Common Stock Certificate </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">333-259891</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10/15/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1851194/000119312524061538/d765460dex102.htm">Form of Registration Rights Agreement, by and among the Company and the Purchasers </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">001-40928</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3/7/2024</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d799026dex51.htm">Opinion of Wilson Sonsini Goodrich&nbsp;&amp; Rosati, Professional Corporation </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d799026dex231.htm">Consent of Independent Registered Public Accounting Firm </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">X</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Incorporation by Reference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Form</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>File</B><br><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B><br><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Filing</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Filed</B><br><B>Herewith</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d799026dex51.htm">Consent of Wilson Sonsini Goodrich&nbsp;&amp; Rosati, Professional Corporation (included in the opinion filed as Exhibit&nbsp;5.1 to this Registration Statement) </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d799026ds3.htm#sig">Power of Attorney (included on the signature page to this Registration Statement) </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d799026dexfilingfees.htm">Filing Fee Table </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">X</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&#8201;17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Undertakings </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The undersigned registrant hereby undertakes: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(1) to file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) to include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities
offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the
Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#147;Calculation of Filing Fee Tables&#148; or &#147;Calculation
of Registration Fee&#148; table, as applicable, in the effective registration statement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) to include any material information
with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I>, <I>however</I>, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) do not apply if the information required to be included in a
post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act that are incorporated by reference in the
registration statement, or is contained in a form of prospectus filed pursuant to Rule&nbsp;424(b) that is part of the registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(2) that, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a
new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide </I>offering thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(3) to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(4) that, for the purpose of determining liability under the Securities Act to any purchaser: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) each prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(3) shall be deemed to be part of the registration statement as of the
date the filed prospectus was deemed part of and included in the registration statement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) each prospectus required to be filed
pursuant to Rule&nbsp;424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule&nbsp;430B relating to an offering made pursuant to Rule&nbsp;415(a)(1)(i), (vii)&nbsp;or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(x)&nbsp;for the purpose of providing the information required by Section&nbsp;10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the
earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule&nbsp;430B, for liability purposes of the issuer
and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of
such securities at that time shall be deemed to be the initial <I>bona fide </I>offering thereof. <I>Provided, however</I>, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a
document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or
modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(5) that, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of
the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser,
if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to
Rule&nbsp;424; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used
or referred to by the undersigned registrant; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) the portion of any other free writing prospectus relating to the offering containing
material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)
any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(6) that, for purposes of
determining any liability under the Securities Act, each filing of the registrant&#146;s annual report pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#146;s annual report
pursuant to Section&nbsp;15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
that time shall be deemed to be the initial <I>bona fide</I> offering thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Insofar as indemnification for liabilities arising
under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification
is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a
director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant
will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities
Act and will be governed by the final adjudication of such issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets
all of the requirements for filing on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego,
California, on April 9, 2024. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>VENTYX BIOSCIENCES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Raju Mohan, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Raju Mohan, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Raju Mohan, Ph.D. and
Martin Auster, M.D., and each of them, as his or her true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent, with full power of substitution and resubstitution, for him or her and
in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this registration statement, including post-effective amendments, and registration statements filed pursuant to Rule&nbsp;462 under the Securities Act,
and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection
therewith and about the premises, as fully for all intents and purposes as they, he or she might or could do in person, hereby ratifying and confirming all that said
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent or any of them, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the
capacities and on the dates indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Raju Mohan, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Raju Mohan, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Executive Officer and Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Principal Executive Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>April 9, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Martin Auster, M.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Martin Auster, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Principal Financial and Accounting Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>April 9, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sheila Gujrathi, M.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sheila Gujrathi, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Executive Chairperson</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>April 9, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Onaiza Cadoret-Manier, M.B.A.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Onaiza Cadoret-Manier, M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>April 9, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Allison J. Hulme, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Allison J. Hulme, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>April 9, 2024</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Somasundaram Subramaniam, M.B.A.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Somasundaram Subramaniam, M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>April 9, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ William White, J.D., M.P.P.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">William White, J.D., M.P.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>April 9, 2024</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d799026dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g799026g0404130120124.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wilson Sonsini Goodrich&nbsp;&amp; Rosati Professional Corporation</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12235 El Camino Real</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California 92130-3002</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SMALL>O</SMALL>: 858.350.2300</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><SMALL>F</SMALL>:
866.974.7329</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">April 9, 2024 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ventyx Biosciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12790 El Camino Real, Suite 200 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is furnished
to you in connection with the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (the &#147;<U>Registration Statement</U>&#148;), filed by Ventyx Biosciences, Inc. (the &#147;<U>Company</U>&#148;) with the Securities and
Exchange Commission (the &#147;<U>Commission</U>&#148;) on the date hereof in connection with the registration under the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;), of the offer and resale of 11,174,000 shares (the
&#147;<U>Shares</U>&#148;) of the Company&#146;s common stock, $0.0001 par value per share (the &#147;<U>Shares</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are acting
as counsel for the Company in connection with the registration of the Shares for offer and resale. As such counsel, we have made such legal and factual examinations and inquiries as we have deemed necessary or advisable for the purpose of rendering
the opinions and statements set forth below. In rendering the opinions and statements expressed below, we have examined originals or copies, certified or otherwise identified to our satisfaction, of such documents, corporate records, certificates of
public officials and other instruments as we have deemed necessary for the purposes of rendering this opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have
reviewed originals or copies of such corporate records of the Company, certificates of public officials, a certificate of an officer of the Company as to factual matters and such other documents which we consider necessary or advisable for the
purpose of rendering the opinions set forth below. We have not independently established the facts stated therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our examination, we
have assumed the genuineness of all signatures, the authenticity and completeness of all documents submitted to us as originals, the conformity with the originals of all documents submitted to us as copies, the authenticity of the originals of such
documents and the legal competence of all signatories to such documents. We have also assumed the authority of such persons signing on behalf of the parties thereto other than the Company and the due authorization, execution and delivery of all
documents by the parties thereto other than the Company. We have also assumed<I> </I>the conformity of the documents filed with the Commission via the Electronic Data Gathering, Analysis and Retrieval System (&#147;<U>EDGAR</U>&#148;), except for
required EDGAR formatting changes, to physical copies submitted for our examination and the absence of any evidence extrinsic to the provisions of the written agreements between the parties that the parties intended a meaning contrary to that
expressed by those provisions. </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">AUSTIN&#8195;&#8195;BEIJING&#8195;&#8195;BOSTON&#8195;&#8195;BOULDER&#8195;&#8195;BRUSSELS&#8195;&#8195;HONG
KONG&#8195;&#8195;LONDON&#8195;&#8195;LOS ANGELES&#8195;&#8195;NEW YORK&#8195;&#8195;PALO ALTO </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">SALT LAKE CITY&#8195;&#8195;SAN
DIEGO&#8195;&#8195;SAN FRANCISCO&#8195;&#8195;SEATTLE&#8195;&#8195;SHANGHAI&#8195;&#8195;WASHINGTON, DC&#8195;&#8195;WILMINGTON, DE </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g799026g0404130120377.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the basis of the foregoing, we are of the opinion that the Shares are duly authorized,
validly issued, fully paid and nonassessable. It is understood that this opinion is to be used only in connection with the offer and resale of the Shares while the Registration Statement is in effect. We assume no obligation to supplement this
opinion if any applicable law changes after the date hereof or if we become aware of any fact that might change the opinion expressed herein after the date hereof. We express no opinion as to the laws of any other jurisdiction, other than the
federal laws of the United States of America and the General Corporation Law of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We consent to the use of this
opinion as an exhibit to the Registration Statement, and we consent to the reference of our name under the caption &#147;Legal Matters&#148; in the prospectus forming part of the Registration Statement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Wilson Sonsini Goodrich&nbsp;&amp; Rosati</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WILSON SONSINI GOODRICH&nbsp;&amp; ROSATI</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Professional Corporation</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d799026dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Consent of Independent Registered Public Accounting Firm </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We&nbsp;consent&nbsp;to the reference to our firm under the caption &#147;Experts&#148; in the Registration Statement
<FONT STYLE="white-space:nowrap">(Form&nbsp;S-3)</FONT> and related Prospectus of Ventyx Biosciences, Inc. for the registration of 11,174,000&nbsp;shares of common stock and to the incorporation by reference therein of our reports dated
February&nbsp;27, 2024, with respect to the consolidated financial statements of Ventyx Biosciences, Inc., and the effectiveness of internal control over financial reporting of Ventyx Biosciences, Inc., included in its Annual Report <FONT
STYLE="white-space:nowrap">(Form&nbsp;10-K)</FONT> for the year ended December&nbsp;31, 2023 filed with the Securities and Exchange Commission. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April 9, 2024 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>d799026dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Tables </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form S-3</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ventyx Biosciences, Inc.</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table 1: Newly Registered and Carry Forward Securities</B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Security<BR>Type</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Security<BR>Class Title</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Fee<BR>Calculation<BR>or Carry<BR>Forward<BR>Rule</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Amount<BR>Registered</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Proposed<BR>Maximum<BR>Offering<BR>Price Per<BR>Unit</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Maximum<BR>Aggregate<BR>Offering Price</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Fee Rate</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Amount of<BR>Registration<BR>Fee</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Carry<BR>Forward<BR>Form<BR>Type</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Carry<BR>Forward<BR>File<BR>Number</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Carry<BR>Forward<BR>Initial<BR>effective<BR>date</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt"><B>Filing Fee<BR>Previously<BR>Paid In<BR>Connection<BR>with<BR>Unsold<BR>Securities<BR>to be<BR>Carried<BR>Forward</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="25" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="25" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt"><B>Newly Registered Securities</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Fees to Be</B>&#8194;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Paid</B>&#8194;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"><B></B>Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Common Stock,<BR>par&nbsp;value</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">$0.0001 per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">457(c)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">11,174,000 (1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$5.265 (2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$58,831,110</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">0.0001476</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$8,683.48</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;&#8194;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Fees</B>&#8194;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Previously</B>&#8194;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Paid</B>&#8194;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"><B></B>&#151;&#8194;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;&#8194;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="25" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="25" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt"><B>Carry Forward Securities</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Carry</B>&#8194;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Forward</B>&#8194;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Securities</B>&#8194;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;"><B></B>&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;&#8194;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="right" STYLE="padding-bottom:1pt ;"><B>Total Offering Amounts</B>&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$58,831,110</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$8,683.48</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="right" STYLE="padding-bottom:1pt ;"><B>Total Fees Previously Paid</B>&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="right" STYLE="padding-bottom:1pt ;"><B>Total Fee Offsets</B>&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&#8194;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="right" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000"><B>Net Fee Due</B>&#8201;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">$8,683.48</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the shares of Common Stock, $0.0001 par value per share (the &#147;Common Stock&#148;) of Ventyx
Biosciences, Inc. that will be offered for resale by the selling stockholders pursuant to the prospectus to which this exhibit is attached. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), the
registrant is also registering an indeterminate number of additional shares of common stock issuable by reason of any stock dividend, stock split, recapitalization or other similar transaction. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) of the Securities
Act, and based upon the average of the high and low prices for a share of the registrant&#146;s common stock as reported on the Nasdaq Global Select Market on April 3, 2024 (such date being within five business days of the date that this
registration statement was filed with the U.S. Securities and Exchange Commission). </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g799026g03g03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g799026g03g03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1N<4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &X"^<$ X0DE-! 0      %L< 5H  QLE1QP"   "   < E  "')R-C$S
M,C<W' (% #I-:6-R;W-O9G0@5V]R9" M(%9E;G1Y>" M(#(P,C0@4$E012 M
M($9O<FT@4RTS(%)E<V%L92YD;V-X #A"24T$)0      $(XRZ&-1_WNV=?%P
M&M[]4=0X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-0>&Q ;             IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8
M  X             /X   #A"24T$#0      !    %HX0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M      $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE-
M _@      '   /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z   .$))300(       0
M 0   D    )      #A"24T$'@      !      X0DE-!!H      T$    &
M              #I   #&@    8 9P P #, 9P P #,    !
M              $              QH   #I                      $
M                        $     $       !N=6QL     @    9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<   #I     %)G:'1L;VYG   #&@
M  9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L
M:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU
M;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU
M;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG    Z0    !29VAT;&]N9P   QH    #=7)L5$585     $
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MMW0.N6FCI^3NO +O2>UU
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,SAT>(&SM_ :-3="L;3!)B@V1$5&4EAF9VC1U__$ !T!  $%  ,!
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M6$C*>YDX9VX;RD6CW&4(Q?R#=,A&<6D1.J=[6A8)(KE"!TS,8Z@*  ''W)&
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MHJ@3EQDJ5"*&'3CW+ DYR>23SW.1I\++XEK80^>LV*-#W, L]=(-$A/0Z&!
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M$(DW4.<"Z:-P^#VZMLVJLO%SGLXI:)%>5(:V5YV#R"-1%&U+&')8C@,!C))
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MS>O(QZ#5@ZL4!*4??ZD^G ?_ !>WY_7\Q^@<_7VTQUARA/<_-[X]/_3\-?>
MWWAP.V.0!SR .Q/.>#Z#TU:"HI@";0 ^O87GVX]^ 'D/U\?ER/[ #GC49K,G
M.,G(88'))"G)Q[?7&?? SI? 1@D<_*,X_#OGG\..WOC(U/D=&M96/=QCU,J[
M*1:KL72)N1*JV=(F073,'(?=,FJ8H^X"(_GS[:C,Y*JS'AE8,/<'/[^?3L!D
M=\ !-<*:*MHZNDGC\R.J@D@D5L$,DH*OU GD='5C/.<$8(SI<N +;+X&W"4Z
MY@=8#X_O7H)LJ B(O(5-TX@;*TX-XTU1>1"\B"8G[4_(9%4!)P @W7RE2MMU
M5 5P983(F1D]0RZE3W[])^H!4Y['"_A?<J[P[\4;1=R64;?W%)05X7*B:WF2
M2VU\97*JQ>DDFD0-E>L1NI!(UL9;KI.D$7+=0JJ#A)-=%4@\D426(51-0H_F
M4Y#%,4?S 0'5#D%25(P5)!'L0<$?OU[5HZR(DB,&215=&!R&5P&5@?4$$$'V
MU'.3<,8AS3#A7\O8OQ_D^$*!P3C+]4(&V,T!4 2J&:I3;%Z5JH<HB4RC?Q*"
M41*)N!'2JCN%?;I?.M];544O8R4L\L#D>Q:)T)'T.1]-<9(HY1TR1I(/9U##
MN#Z@^H'[M>:;U(MKR^S;>GFO"S5F#6JQEK4MV-?(B"S5;'%Q-]HZ<@0%P,1X
MG"LG8UEZ90#IJ2$(_(?N*!BAZ >'.Y?Y6[-MM<\K&M,<E%<6Z@'%93IT2OD-
ME>M3'*G8X;(/8BL[I3"WW&48_5D^8G!Q@D-T^W"C&!GWQDY/H(=-JUX2R9LW
MP9EO!^.L?8UAL@T2&>6>OX]JD#4XUE>X5(U=O$:NT@VC4JYHFV14PP:.'8&<
M+,$6J_!"*D*&'-YTESMVY;O;+I65-;/0ULT4<U3-+,STY/F4TBM*[D"2G>-\
M X'41Z:L6A>*2D@DA551XU("A1SC!X7CN-7MU%]*]8V?B;+?AZ*N&"<,TK&N
M/&V9K E*98R/>H>G0"&07%=64=5.D5YS8V; DR\;6"30M,@]8N79U%E*_!*
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MO@_Y9Z_KZDXY[:]1_#.[?IO8>V*]L^8;5!2S=7+&:@S12,W))+M3F3)Y/5G
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M\FK+B_HHO]&G^R-2?I%KLUA(^)K#_P _3&H^W/\ <O4;\O\ [EY:X_;[<?\
M'&MC_9R_P6O(]/TZ?^#H_P#J?WG4"W63\93]_P"YF_BSC^S^&=:1NA7_ !6V
MV+_-LG?[X;]J@_%__&'N+W\^G_X.GU*;+_>NC_T*_P!FJ<_$Y!SL2Q5[_3='
M3A_HQAEWVU*/L^?X=S#WL5P_WU'_ -?X:0[G_O9_\Q%_%9!_SS^6JG_"N?\
M-V]3_/<%?[#*NI7]I+^Z=J?ZO<_]NB_Z_P!ND>TOZ"J_TB?[)UKGUF'4NT:-
M&L,OQ)>TG]%>YJG;H*O$BWJ&X:$",M[ANB(-6F6:.U;L7"BYB%*FW/:*:$*]
M;AR"CM_ V%V?DYC''7WV?-SFML];MJIES46J;XJB1V&6H:D@-&H+9*P3^86Q
MD*LD:@<Z@^YZ+HFCK8QTB13'*<\%@"!GT ((R/4DYSG&FK?#:;L?TJ[7;AMG
ML<H9S;=N5@*[K*+A0HKKXKOKI])1238##Y5TZ[:T+''K< 9-BPD:^U Q2J(I
MEK3QXVT+3NF.\T\712W^$S/TCY5KZ?ICJ1V 'FH8I1R2S&0^FG?;E7\11>2Q
M'F4S=##G/2Q)!/OSGMCTXUH>NMPKV/:?:K[;9!&)JU*KLU:['*.! J,=!U^.
M<RLJ\4$1#[K=DU75[0'DW;VA[B :I&G@DJJB"FA3S)JB6.&%!W:25U1 /Q9@
M,^F=/[,$5G8X506)]@!DZPP])FEV+J)]76V[I<AL3NH*BV6V;CK&V<@+IDTF
M',D:)Q'4BKG(=,0@7[N+?QZ9@)Y6-)7(!2@)PUKGQ-J8MB>&%LVE22!:JLAA
MMC=+GK:$#XFX2GMU+*_5$?0"=?8:A5I4W*\5%;(A"PN60X^4D95!WX^7#'(.
M<_7(WB:R#J;Z-&C69+X@'IB&S927N]7"4 9?+.-()!+,-:B&ASO<AXWB"&*G
M:6K5H@=1_;: T'O=&.)%9*DMG")E5EZY#LE[[\%?$3^3]>NV;M.5L]RF'P<S
ML>FWULI"]().$IZH_*X PLY20X#.=1R_VOXN U$"_P XB&6Z>\B*#QCU(R?K
M@Y'(&LV&UGJF;G-I6V[..VG&$N 5S+K;NJT\X>N/GF')B7$C&XS5  B*OB=V
MJ"_<94S.&Z<#.)H6N)(G+>K!]?\ NGPOL&Z+_:MRU@6/X(++<(( C+=8H@KT
MR3XQE8W #R_.TD75$PZ N(U0WNHIJ22C'+LOEQ-D@QNWRG!P<GTSD8.#G()U
MJ.Z$/2Y-MDQ\ANOSE J);A,M5\HU& F&X^OQ-CB9*5T5-=-<!6:WB[MA:O;$
M*Y0?P<05I7A%JZ<V-LXS?XO^(0W+<#M^SR"/;]I<1YB^5:VKB'09<@D-!!RD
M (Z68&0 @(1*K);32Q?$5'SU<V69V^\H;/'(!#$'G@8''J<Z+M4KI^T:-&J
M[H+H 6XD,5000A&#5,Y.X>WU3TOK%5   #DPI*M2&X$>WP@///)2S;;L'11R
M2X ::3I+>H3[HP>^"0>Q'WNV1G5$>)MW'Z6BH_,^2BIT)7)QYLP,A)&,9"]
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M_>JA_P! G]FJ<_$Y  [$L5<__-'3A#^7]%^7M2G[/G^'<WM^@KAD_P#QJ/\
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M6RS3N]OKXXV:G$3.S+3RN,B*:%2$(D(,@7K7/(6=6RYP5\"LK@2KA)$8_,6
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M/>JBW4^"HCZ X/(=\@,_ORH^@Y/MQZ+E I%=QG1:;CJHL$XNJT2KP-0KL<B
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MW/KG-/WLBYDGK6.8)*/'\D^0CV#5(!,JY=O%B(-4$RA[F476532*  (B8P
MB)M.CN(D=\_=!))[!57J)/L.#S[=M4]+42UE5!1TRM-4U=1'34\2Y9I)II!'
M&N/=W8#V!/?U&F? ^+F.'<55&B-"$]7&QJ3B==% H'D+$_ '4T]4,'N<#O5%
M$F_<(BFS1;H /:D4 JFNJ7JZJ:=B3UNW3DGA<_+C/N.?Q.O2S96VH-I;8M-C
MA +TE*AJY?VIZV4"2JF<X&2TS,%_JQJBC 4:A'?ID.Z4G;I8ZSBE(76:LWR<
M1@;#C--11-<MUR:JK#N+ 51$#*H-J%42V?(<D\ ADF,;5';IP)44CF!XVK24
MM3>:>:X8%LMJR76XEL=+4U"OG>0<\$U4RQ4JJ.6:8 <Z7;AJ9H+7-%2@FMKR
MMNH@!DBIJ\Q+(<=D@0O.[=E2-F.<8/?MIFVBC;1L"4'!="2*HPJ<6F,Y.'1*
MB^MMN>D(O9;7)@ F'U4S)>55% 5%"1L<1C$M3 SCVQ")]Q7VKW)>*V[UAQ)5
M2GRH5+&.EID^6GI8NHDB*"(*B\Y)!8_,Q.NVQV>FL5LI;;3#*PIF64@!IZA_
MFFG?_*D<D@?LKTKG"ZL=IDT[Z_@B !R(@ !R(B(\  ![B//[ ]QU\) [^IQ^
M>C2$W^8"=1[J4T+$U'=&F-J>QZ4/F"[R[ _DA,C9NA7"D91C*N"F.W?0E=LG
ME4K1"%%O,$@[A(=[Q@YC%6UQBSG8WA_-=Z]!'N+>:K0VN,DK/06?IZJZ8#AD
M>KC=(I PZD62+!!ZM5G^DANO=\%#2-YEFVT[U=:Z\Q55RPR4JD\AXX9 TD1'
M#-'(V2,:?;JG=69I(G4$RL?(&3&&,(E<%*[C?N-)"F8XIO;?(H%%V8W:;QG+
M#,#)QZ0\"=%XM*IFX#LU/-LT(BIWK)!S-\B^AZ.XZ3WY(#'!]OQUC#[0.Z?T
MW?J;:M))U45B;SJSI)Z)+E-&,AL'#?"Q-Y8&#TRO*,Y[4ZA( P^, 3Y$! .>
M.!]A#CG\^1]P_8'Y?EJ4%@H Y8KG#-DXR03[>WX#C&J<H;<6(POUP .1QR?;
MV&,YQVX&FE;!(OY?/7\PIB058*%#D0XY K]V/T_+W'V#V]@^FH7NHY^$/&<R
M=LD>GJ>__7U]M2^!%+\-/?N/O4U#S^$D_M^/;\?7.F;:A^M&Z-&C2ONKCL4E
M-_6TN4QE22P:.7JA:8*^8I?V!X>,BRS;%8\7.Q$A*)-W:K-A-U63F&XF!NJC
M\T0B%UR"1L!R3SPYW>-E[EI[K,LLE!)%-37""'EY(9$+(R(71&>.<1L.H@=/
M7W)QIMNM#\?2/ N!)D-&Q[!LX.?H5)_/![@:4#TL^@WG?;#NJH&XS<O/8CD8
M/&T18IFL5&F3\]99<,B/61(6OO9,9"J0D0G'0K&3FIE%TUDGCE&<80WA;'3.
MLX;6CXD>,UJW1MR:Q6.CN%.]7+ M5458BC0TD9\QXXQ'-(_7(Z1H_4.EHFDR
M2<99[3M^2BJEJ9Y$?RU;RU4=F(Z03D=L%B",$$ XR<C5_K.(&/\ O^/XGUU*
MM&ONC2Z>HATT\&=1/'C&OY!%U3<E5))X?&^7J\S:.+%5UG1#&4B95FX%)*ST
MQ\Z\3F3K+ITS,*R8/(>3AI,?7ZF>R=\WG8UQ:LMC++33]*UUOF9Q3U:IGH+!
M"#'+&6+1RJ<@DAE925*"OM\%PB\N489<F.0 =2,1C//<>XR,^_?./_,/P^74
MBQ+8':F.JC5,VPS%V*D/:<<7^OUZ472%0H-G2T!>9.J2T6_ HB=PBR<2B#4Q
M3 E)N2@54VH+;XZ[&N]+Y5ZBGM[.@,]/5T1K:69P.0!#'.N">1U!3ZD=]0^3
M;EQIG)I9%=<\,AZ&.>Q<%@>."<#'!X.0!S%1Z3O6_P C*.(*>:Y3J$.]*+&2
M<Y'W.,"PBK1PF<52/&$/D*S/W[,X)>%=%"(>B)U4@.B*9CJ)I:GQ*\&J,-/3
M6Z@GF!+**7;JB;J!!/0TU+ B]0&,F1?4\D 'O6V[AD/EM4,J' +-(" .?3JR
M<<# SQCGC3@=DOPWF.,8V*$R=O#R..9[;$NV$NPQM1C2T#CMG*L%4G#96Q6=
MV9I;[L1LNBBH@T1;5&/[DO#(-Y=H<4M5AN[QRN5UI9K5MBWQ6"V3(\,LG1$U
M9- Z-&R!$004RNC$,H\UP. ZZ=:.P+&Z3UD\E3*AZE4L>A6X[D_,P&.,=.<G
M/& &^=1:@[Z<E8=KU4V$Y*JF)\C.[B16ZVZS/FL>K]@RP,TV<1,&[<5"WJLI
M1Y-.XET228-HZ08I1YS-)%(ZH@-8;.JMJT=V%1NZ@JKE;4A/32TI(9IPZ,ID
M*ST[>6%5@5#$,6Y'&=.U>E:\/30R)%-U EW ("@'( ((Y..?3'UUE-MWPZW4
MNOUHL%VNV0L%6FWVN8?V"RV2<RA<)"8G)J4<J.Y&3DGR^/S+.'CMRJ=594QN
M3&,/'   !I>B\=]A6^A@MU%9[Q3T=-"*>&".&F"1P+D+$H-22$"D#!)./7/.
MHG)MJX32M-+51&5FZB_.2<YYXY]N3G'KI_O2]VZ]5;;G<9"J[RLWTG+V F^/
M%(6F132W*VFU5.UQK^ 3@UT):3Q]"V%_"_9YI*Q2K*1L[ILU.=JY0:"L!SC1
M6_[SL"]"*JVG9JZTW!ZAY*TRX6FGCD\QF(A$\JQR^8RMU( &&01VQ)+=#<8.
MJ.KECEB"@1E3\P(P/ZN<8XP3P1QQC33]Q49F::P9E2(V[SL+6,XR5+FF6+;%
M8BMCPD)<7#84HB4DB/(F=:G;,EC><Q'$/(HF,0I5&BI1$NH!;&MZ7&BDNJ32
M6U*B-JV. XFDI@P,J1GJ3#,HP#U+@G.=.,HD,;B(@2=)Z"WW0WIG@\?E_P!=
M8],Z]"WJY[F;RKDK/.;,-90NZD>C$)SMGR=95U&,0W>/7[>'B637&S2-AX=L
M\D7[AM%13)DP05>.3HH)F6/SJ.P^,?AKMFB-OLEANU!3,WF2)'#"YFFPJF>5
MY*LL\I10K,22555[ 8B-78;E6S>=454;MTE .0 O) '!X!).!C)]M7CZ?_3X
MZS^S*^XFKA<_XJ>[7X*]0Z]^Q :_25EBOL+(3IG=T0IS2Q8P=.*])KHOY.9;
MH5^4@2/YH2@Y=H@Z7<!"-^;T\,=V4]RK(+#=*?<53$33W B.)&J$4)'\0L=0
MRR(5 #%D8@#CD A?;J"ZT)CC:HBDIE;#)SU='LI(XP   /["07R;U=I=#WN[
M<,@;=\@.W,1'6]LS>0=G8-TG4E3[?!NTY.LV=BV6.D1R:-DD$ROF KM?FL0O
M(Q)W39-\=8E1[7W#6;6O=!?*$*TU&Y)ADX2:&12DL+D<KU(QZ6&>APK8;IP7
MJKIHZRGDIY,A9%(R,94XX(R#[X/N"1QWUC;+\/WU2<09(*\P[8Z*"K9P^91&
M5J#F>0QZ[;QBR8)BX=E.WA+=%ED$1*FZCHU"7*4Y5$E%G" )K*ZHD\</#Z]6
M\+?K762R (QH*F@BK4\T*.IXI,^5PQ(4L4.!D^F(<-O72GE<TLZ(APH=&Z6Z
M<YR1\IR>Q X]AJ^N#OAN\E9"G8RZ[^MU,]<5$"-Q<TO'LS/VR<=((F%0D>]R
MID4BRC%L43'3<MHFH.5# JN+&8:J"1SJ"7?QQHJ2&6DV5MB@MBNI3XRJIH(G
MP<?,M)2$1NV>K^FD<'C*<X#E!8)W=9:^NEF*@81"<>GWF;@XQWP2>.00#K5I
M2JC#4"G5.B5PCQ.OTNM0=3@DY&0>2S\D/78QK$1A'LI(K.'\B[*R9HE</GJZ
MSITJ!UW"IU3F,.>JB>2JJ)ZJ;I\VHFEGEZ$6-/,E=I'Z$0*J+U,>E5 51@
M#4F50BJB]D4*/P4 #^ UV;73KEK.]\2)MK@<H;,(?/Q7$7'7';?<(YRV</7#
M9FO.4W),I#U*PUMHJNJB+I^$T:KS\>U**RYB0\BBT1\CU7NNOP*W#-:=X+;
MDLU+?8&II8XPS=$].KSP3D+]U443(S'  D!)P-,.XJ5)Z!Y#@20?.A) _$<]
M\X[>NE.?#.[92WW<MD[<O.L/+"X&IR=7JBJZ7<D.0LEIN6JCQ YRB0[B%I4=
M.H+$*/<D-G9+\$,")ALW[1&XOAK5;-M0-TRW";XZK 8DBEI3B&-QGM).P;G/
M]#QZZ9]JTP=YJI@<HHCC/2.G+G)*GZ*H[>C=_36X361]3;7S/?4^C=>B @O
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MK*P)Z >D?-U%+>]&O:N.W/:7$6FP1A&61,]NFN2[&95$A'S*LKLP0Q[7UC@
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M]Q>5]/;*^KC\VGII)8\D=2E<9'<<L#Q^'O['5>;G\6/#S9ER6T;GW10VBY/
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MLA&R8\*.PKE@:14VJR3-P4SY%@HS 1 //]XO/"JMU;1'^<T\D0_K$!E_-E+
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M SWYZ2<<ZSS]IO\ F]1X976^6^NNGA_:]SS5&\*.DC:6$KY4'P$M="K*)*=
MM6I67$1#O&S!I%#6HJDOT]-U]-3HE6)@6ZQ+R,*W;4]"*KU?MD*W!,K=(T?!
M+M(FUUYZS#QE;.V#=HNW#PG;K^)1(QV^:.]6Z7S9A5QL&R9&+M&_KR<LK*?4
M'\,#MJQ[76^"/B?9ELUL;9E]H'I5CCM44-#3UU%&T81/(HV2"OM\T:E1')#'
M%(F%*/@ ZM=B/%-.PACFK8MH#-VRJ=0C_ET2B_?N)-\8AUE73AP\?.C&57<N
MG2Z[E82@F@0ZHIMD$&Y$T2-L\\E3*\TK=4CG+'&/W#TU9.V]NVO:=CMNW;+#
M)!:[53)2T<4LTE1(L2=NN:4M)(Q))9F/<\ # '*Y$I45DBAW"@SB8*1-PKDO
M7GO)0,*:4HR6:@X3 ?;S-5%".41_ZJR1#?4-?::H>EJ(:B,D/#(DBD?Y)!(_
M,9!_'79N&R4FY+%=[!7J'H[Q;JNW5 (!Q'50/"7 ((ZHRPD0XX=5/IK(#"H3
MFWO<&> MI 8R%,N,A4+48XB"16:ZRD4\D$C'*0ZS%1JX1G6J@E#R-/3+D#M5
M "W[1SQW&EBJ8FRLT9:/T!P,JK9['(Z.QR>H#)&O&"V)7>%/BPEONZ-#)9[[
M-:+D[?=:FJ)33?%(1CJ@EADAN"G (B,;  L%#$;*<#E4. @)3 !RF 0$! 0#
M@0-^91 P?3V$>!#D.!%QI<^8H/<#!YXX]O7)'OCTUOVF='1'4Y$B(X8<J5=>
MI><\$CD9'8'OJMES/]W]G(B/Y^_//UX]O80]N0#GVX]M2> 9*CZ+]!Q_9]/S
MTEFX(_SSQZ9PWK[GMW_+58+48 ,L C[<J '/\H\<?E_JYX]]2BE8 (""<\ #
M!(R< GL<9X)Q@<\XTG. RDY/;(')_' SA0>Y[?\ -H'3!V1JV6RQFZ#*<.=.
MOU]R+C$4%)-C$&<FT1["WMPW7('=$0Q_(%9,)# ^E^9E$R:,6P5?TSXJ;Y!B
M;;%IGSU=(NT\;8"A<YHLC[Q9N92#@* I!ZB1;OAQL]FF7<-RA(6,M^C89 2&
M+$9J2K=E4C]7D'+?.#\H)T(ZH'5WZ-&C1HT:-&C1HT:-&C1HT:2)=L1XVS5U
M=K53<JTZ&O562VR1TV2$GD5'#$DHQ>UUNS?E3342$%T$GSQ),>\/NN50$! W
MM*H*NJH]NI)32M$36D=:## DMG)(((.%^@QZ'ODN\[3V[O#[35?;]SV2DO=!
M!X;T]5#3W"(34R3K7TL8E1.H=,JAV&3_ %@1R.)4W@[(MJ&--O63LKT&D1.$
ML@XQJ,S<J)?*)+RU3EV5LB&AG4"Q!9I*((OS3,DDVAT4'":S@BC\3QYT'@D5
M#JMMXNE16PP2SR54,\@2:%PI5HVX8D!< +GJ/&#T@'C(+]XG^$7ACMW9.X-S
MV>S4.S;SMNV5EXM%^LTT]JJ:6Y4D+2TH9X)D6H^(D5:81RK(Y$I$/3(587*V
M89'MF6]K.$<B7E;U-MLM(9.)Q\*/IS2;QFY=QGS8Z(%(0BDNBR2DU?$0B!E'
M1CH%! R8::KK!%3W&KAA $4<I" =@" V!GL 21CTQCTU:7A)N"Y[I\-=E[@O
M)#72Z6*DJ*UPK)YL^&C,Y5E0J9PBS$=*C,A*@*1JFU _C@LY!_\ C56!_H6H
MP?\ B&G28_\ NW2C!XK)#G''.> >Q/&?IJI[",?:FWN<K\VP;1@9RWR_HWDC
MN >K /K@^VIBZGF(IW,&S[(,;5F+J3LE,>0F1HB,9$.L[?C5'1U91NV;I@)W
M3D(%W*K-FI ,HNY2232*=4Q"&26"H2FN4+2-TI(KPDXR 9!@9QV!.!GTSG4M
M^T3M>NW7X4;AI+9!)57&VFCOU'2Q9,L\MHJ%JFCC4<O)Y(E9(QS(ZA%#,0IF
MW:3N!I^X_!M%O]8F&3V2- 14?<HA)PD>0K5M9,D6\U%2;4H$4;B#Q)9PQ6.B
MDC(1RK9^T 6SA,=);E22T=7-&ZD*9',;#E70L2.D@D'&<'!.""-3'PTWM:M^
M;0LU[MU3%+,]#2Q72E#K\1;[DD*+54M3%P\3K*&,?6BB6(I*@*,#J$^I5G.I
MXGVN9'JSYZBZO.8*Q+XUH52:J%6G)M_;&_R)\]9QZ1_5':0[&06>+N2IBGZD
MK1B05'CUJW656.EDGKH9@OZFFD6:5SPJA/F4$]LD@<>W)XYU$_'K=]#MOPZW
M#0&59;YN:V5=AL5LB/765M7=(S0]<,"GS#'3K4&1Y<!%953JZW4&:MFN+IC#
M&U["N.+$3PV& I3%6?;>W[AFIM=S/R<:(E  .,8\E%H\50 /*+851 !..DMS
MJ%JJ^JG0 (\IZ<=BJ@*"/\['5^>I9X6[=J-J>'FT+!6*(ZVWV2C2MC!SY=9*
MGQ%3&3D]1CFE="P^\5)P,XUR4B&V3="-PH<PUQAF1;'LX[K5MKTJQB+"]JDX
MD4I'2!DGB!WD:N0XF0+(QYDTP=MW#=)WZMFX31X(U=0B.5#/3K*.I'4LBN/?
M^J3CW&1WTIJ4V%X@"YV:LBV]N@VBJEH+G054-)7RV^J"@2Q212JTL#X;I\Q.
MD%@5#]2$!/.^;;;CS8>[QEN2VH2\]BR_O<EP]9/C>-L,G*0-U8O6[]^\;(Q$
MH\?2;AEWLD(Z0ABK/8A1"51*A'LW96R^I1:*V:\)4T-Q5)X4@,HJ&0*T)7@=
M3+T\OW!QU$J<'.-95\6_#S;O@M4[>W_X954^U+W4[AH+1)M^GK:F:VWRFJY&
M::GCMT\LQRN ABC!IU6;Y8D<AB]#(=2+DC&%VHSM0[,MZHMBJ[A4@]BC7[2P
M+N+44*(E-V&0%X)@$2F[1+R)1XXU$8G$,\<@Y$4JO^(1P?7W _'6Q[U;1?+#
M=K1(QB%WM%=;W=<!H_CJ.6F9AW&4\TGU''J-+4Z5.6VD9BV6VD7Y9&M9KV_6
MBW03^GR0E:2,G7'L^\G$9J*35[?F+5"0F'K5<[8[@Y6H1LF8?02K!95_W'3E
MZA+E"A-+611,'4<*Z1B,JV.!D(".PSD=P=9\^S5N2*EVO/X8WIEM^[-AW*Y6
MJ:V5+!*FIH35R5D%=3A@IJ(6-4ZET,AZ5CF8^7/$S,QR+DBBXEI\Q?<CV:+J
M-1@D 7DYJ66%)NB!S FB@BFF51R\>N53%19L&2+AZ\7,1%L@JJ8I!C\,$M1(
ML4*-)(V<*OL.Y)[ #U)(&M#7N^6C;EMJ;O?+A2VNVTB]=165<@BB0$X5<GEG
M<D*D:!G=B JD\:Y:IVNMWJM0=QJ$RQL-7LL:UF(*;C%@<,).,>I%6:O&JH '
M<DJF8#!R!3%'DIRE.4Q0XR1O$[1R*5=&*LI[JP."#^!TJH*^CNE%2W&WU$57
M0UL$=325,+=<4\$RAXY8V]5=2"/X@'2P^GZ8!W,]1T/H/Z>HX0_D]5=/Z/K]
M-/\ >?[@LO\ JC?VIK.O@@"-_P#CT",9WQ$1SR5*5F#CTR00/PSKC>L<U;OM
MO^(&3M)-=H]W*X\:.FZH=R:[9S!7)%PBH'MRFHB<Y#AR'(&XY#WURVPSI73M
M&W2PHIR#SQCH)[=N/7VSI+]JR&"IV/M:DJ8_.@JO$7;-/+ 0"L\4JURRPR ]
MXFB+^8#@%0<G5HB=/39.)"B.VW&1N2E$3#$+"(\@'OR+L1]_K]?J(C]1YT@6
M]7:/A*^=0"<!6 '.?0@CU]<_V:LA/ WP@"@#P\VP 1DXMZ<D\DY!]>Y]\GWU
M8_&N+<>X=JR%)QA4HBE5-L[>/V\#!HG;QZ+R05\SUPFD=102J.5?Q%1 W!C\
MFXY$=(*BHGJI6FJ)&EE8 ,[8ZB ,#. .PXU/[%8+-MFW16BP6VEM-L@:1X:*
MCC\JGB:5S)(40$A>MRSM[LQ/<G2UKA_'%XG_ &[6IS_O]V'4@BXVM5=_FN,)
M''&  ._O_P!_C0]T/_YH=LCCGPWN8'(SD5E4>%[XP>3V!P-?OOHQ%=,.WVO;
M^]O<<HK><=-TH_-M,CR&2;Y+Q>'X<B\?MVZ9Q>2,,S B+I<R"SA.-18RR9O/
M5V9#]=JJHZF%K36<Q29-+(W>*7N%#'[JYRR\X!ZAP&.CQ>VQ=ML7NA\:-DPR
MM>;%"*;=MHIR5BW%MOJZJEY84#":KHHQU!PAE,2)(&+TD2ZC+IH9+KN9-UN^
MW*=4,X&OWMQB>PQ9728HN4&[UI9Q4:.T1Y\;MFY*LT<E*8Z8+(J>(ZB?:<RK
M<%-+1T%JII>3$)0#Z$#I P1Q[GCCD'U),?\  #<UJWEXB>,6Z+-(9*&[S;9J
M(6;*NH^#JE>*2,D]$L,H>.3T9AE2R]),N]6.DVI[A;'.9*?%J34CMURU7<H2
ML>D4PJ&K+$JGS1V(E'N!JP>-XEU(F @^"-3=O!.0K4P'2[<EB6JFII6Z15P-
M"K$X'6<](.>/FZB!GUP/74C^TM:;E)M"R;KM-(]=4[#W-;]RSTT2%Y'MU.Q^
M,<*,DI"5AEF( *0++(&4IRP'#V7Z'G/'U>R1CJ?8S]>GV*#@%&JZ2CF->BDF
M9Y#RS8AS*1\O&K'%N^8N"D615+SVBF=,YV6JII:29X9D*LI./9ESPRGLRD=B
M"?8\ZNO:FZK)O.Q4&X=OU]/<;=7PI(DT#JQCDP/-IYT!+0U$+Y26)P'1AVP0
M3^%GSCB2F9!IV*K/?:_#9#O_ )OLC4W3L?FTQX3 0 312(H5KZE3N28>N.V"
M162<),1<*-URIB4M1)"]0D3&&,X>3@*#Z]R,XXSTYQD9URKMU[=MEYMFWJZ\
M45->[P)&MMMDE'Q54L0RQ2-02H[]!?I#D,$ZB"! G43_ ,B7<;[<_P"#]<?Z
M)2,$?Y/I]=++(0+K0DYP)@>!D_=;&![ZA?C>,^$N_LX _DY7$YQC'2N>_'[^
M/?5?MI&QS:3=ML>!;C;<"T"P6BS8JI4U/S<C'+*O926?P;-P]>NSD<D(==PN
M<RBAP('<<1,/(CSI=<+W=8Z^K2.NF5$J)%494@*CD+W4^@SCM^X:A7AQX->%
MM?L/9MPKMB[?J:^MVS9*JKJ9Z&/XB:>:@@EDDF*L 9&D=F;C[Q.KW8DV]X5P
M,2>3P]C>M8])9S1QY\M=:J-@E31 /2QHN@465[O1!)/O !>T"^J6$0$3::*J
MNJZYE>KG>=E&%+D?*#C.   ,X&>.<#/8:N#;.RMI[,CJH=JV&W6**M:)ZJ*W
MP^2D[0^;Y32+D@E/-EZ3Q]]M<E=,D8AB;-7,3W^T4]K8\DLI3[.TNS+L1/:V
M<<9LG(MT6,@4S1X'>[0(FS7Y4>F\I6J+@6[@$NN**<JT\*OTQ$=3H2"A/8\'
MJ'U([#O@:4W6][:@K:+;MZK[9'67V.H%%:KA)#FY1PA1/&D$_P"KG&' ,; ^
M9\P56Z6 HYN/Z:>S^W5.UW*.J4;@VU0</(3S._4)XO5(R!=12"TBG(OZ\V7)
M5S-$S)F!XHC%-7X-C'!H];.$VZJ3Q0WZYI)'"\AK(F94,,P$C,I(& [ L".X
M))]<\9U3?B!]G_PKO-MN5WCM-+M&ZT=+/707^QRO:EH9J:-YEJIJ6!TH)8TZ
M?UG53A_+_HY$=8V7M'2[RCD#+.T.G3V1Y5_8)N&GK-46-DE#+K2,_ U]XFWB
MG[QXY#SR+A BBD4I(+'5<NQCO(]65>BY./7N"GAIKBT<$?E*T,,K)D$"21.I
M\ <*,_LC 'H-+_LY;GON[/"ZUW#<%1)75M)77*TPW.42>9=**W3B"EKB\H$D
MOF+U)YSEGD\K,CO)U,6&Z9-7KI,?5!V63.1T2[@L4P[F6MT/&IQ^0JM&-3N7
M]C@F"1BL;%%MD?Q74M"-@.TD6:*2SN3B2M1:E%Q%D0=S_9VX$I&_1E8R+3R-
MUT\LC8$<A(8QDG@!VY0D@*Q.2.K6(?M9>!-;N^F7Q#VA1RU>X+93""^6NEB,
MM1=;9"D@CJJ:)?GEK*%6*R0H&DJ:;I$8,E.D<BWL)90+;ZF%8F''-HJJ!6AR
M*'*"TE#(F!!H^$!$#JKM.$V$C[ <JQ$7"P +PI26Y  2LJD,KX[*3EF[=(4G
M&<\=^,^QU5?@;X@I?;.=MW.=DOMB1(&CJ,"2KHH6,,$BDD.:B $PS@H#\O65
M .OTMX*J*)I)D.HHJ;L323#O445./8F0A"@)SF./!" 4!,)N"@ CJ0Q_JU$L
MI6*(??E=E5$4#)9B3\HQC.<'^W5XR1R/(8XE$K]6!'&>N5F.0 J 9)[^A!XY
M'K<S:ITZIO(<O&Y%SS%O*_0FRB+^*HKL%&<];SD,55$TVW,4KF%K:H?XYJMZ
M>7E$_N%(R:&*Y<5[NWQ,CI8I;;MYQ)5$&*:XJ5:*!2,,*4@#KE;./,)*+W'4
MPQJT-H>'LL[Q7*^1M#"HZH:1B1/,I.<3C \N(X&5(\QAQ\H^;3Y&3)G&LVD=
M'M6[%@P;(,V3)JD1!JT:-DBHMVS=!(I4T4$$2$2223*4B:92D* %  U0[NTC
MM([,[NS.[L2S,S$LS,3R68DDD\DG)U=Z(D:+'&JHB*$1% 5551A54#@    #
M@#C7TZXZY:-&C1HT:-&C1HT:-&C1HT:H1G/IYXLSOE][F^4R=GC'UX?5R,JJ
MZ^*[M U-J,1%E$J:(*+4V5EQ!R()G>)'EC-EE$$#E;IBD73M2WBII*84BQ4T
ML/69.F:-W/423GB10.Y_9_'.J9WGX'[8WKN<[NJ[WO"R7HVV*U-/MN]16I7H
MXFZUC?\ F$\S=38+@S=!*J0@(SJ,0Z3. Y.2C'5^RMN;RQ%1;@CDM5R/EEM,
M5UTH0Y#\.4HZJP\J0A^SL4!C+,S*$$2G,(<<*#N&K /ET]#"W.'B@=77/J#Y
MI!/ [@]NVHZ/LT[)GJ();UN+Q W+302+(+9?]S_&6Z4H056:&.AIY&3(!(29
M"Q'S$CC3,(*"AZQ"Q5<KT:SAX*#CVD3#Q4>@1LQCHU@@1LS9-&Z8%(BW;()D
M223*  4A0#3&[M(S.[%G8EF8]R3W)UH"DI*:AIJ>CHX8Z:EI88X*>"%0D4,,
M2!(XT1<!51%"J!V &H.B-M5%A=R-JW1-92U'O]OHK#'\G$KO8DU21AXY2+.B
MZ9,4X1*82DS_ "EL595:=<-3%,KVLR&,4Q%;5\[4,=O/3Y$<K2KWZ@S9SSG&
M.?;W^F(A2[ L5'ONY^(D1K/T_=K33V6J#2Q&C^#IC"8_+B$"S"3,"%BU0ZDY
M(0:L*( 8!*8 $H@(" @ @("' @(#[" A[" ^PAI%V[:FY (((R#P0>Q'L=+F
MR3TS,)VFY2N1,7W'*^W&Z3JIEYM]A.V?9J(F'!UR.%5WT"LT=-T3**D%8Z$2
MXBF2CDYW:[19R8RIGNGOE3%&L,\4%9$GW5J$ZCC)P.H=P,X&02!QG5%W[P V
MA<;O/?[!<]R[%N]66:LGVC=I+;35CNW6TE10E)*<LS9<^4(D9R79&?G78<(]
M.K!V(+PVRK/3&0<X978G25C+[F>R%M<A"*HD,1)2$9$9,F+55 3G49.WR<G(
MQRAS#'O6H<%#C5WNJJ8C3QI%24Y.3%3KT=6220S9R1Z8 &1WSWTNVEX&;/VQ
M>4W-65%ZW;N>)>FGOFZ[@;G4TB\\4<71%3P$$EDD,<DT9.$E50H%^=,VKFTO
MO-/3=P1EB\O,J5R8R+@S*$BHX<RESPQ9B55S,O'1.UP[EF"S%^S,X<FX6?.(
MHL0[DEP%:0<N3G5%1ZI;[64\2T\BQ55.H*K%4+U=(..%8$$8QQD-CT],4KNS
MP(V9N6[S;CHI[WM#<=2S/4WG:5Q-JJ:N1PH>2KC$<D4LC]*EY%6.20CYW8%P
MWP8KZ;&(:/D&$RMD.^Y<W"WZL+%<UF2S-:TK%%UYXBOZAL_BX=)@V+ZMNL":
MZ7S!W(,T7B*#]JS;/4BKZ*B^5$L#T\$,%'%)]\4ZLK,.<@L3VYQGI#8SS[=.
MVO ;;%EO-)N*]7G<^^+U;R6M]7NZYBY14+]2LLM+3"&-$E5D1@S,Z!T21$60
M%BQ/3+J\-4WW&[%L$;EI>/M]I96*F9*B ;%BLHXUF2U:[M2LS=S1-9\+1\QD
M2MN1(V5D(]P]9)F,1@[:<\@Z4-WK*%&B1EEIW/S03+UQX]0O(*Y[G!QGG&JK
MWYX.;+\0*JFNMTIZRV[@HNCX/<=AJWMEX@\L_(#41JR3JH^51/%(R*2(V3.=
M017>E?B1:P1,[FC+>>-Q;:OK@O"5;*]Y&1J38Y2I$3.ZC&;-N\>G*1($U$S2
M:+)ZD8Z,@R=I=A"+)-PU'E&*EIJ6CZ@0\D,8\PY[D,>Q//OC)QC)U$*+[.FV
M)*ZDK=V;EWGOM*!Q)1VW<U[>HM4<BXZ9)J*".%:EUQ@><[(02'1Q@!FK%BRC
M&3.-C6C9A'Q[5!DP8LT$VS1DS:I$0;-6K9$I$6[=NBF1)%%(A4TDR%(0I2E
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M-;S*BY %)9650>**)**$,?@XZ?*+<E[M\?E4UPF2(# 1B) H'.%ZP2HS@X!
MX'IJM;KX0>&]XOT6Z*K:MNBW#"SN+O0+);JR5Y%Z)&JGH9(%K&9206JDF89)
M4ACG7>J5M[POCUZG*53'=>8RZ)N]"9=-E)B8:G$@$$6<I,JOWS(#% >XK-=
M@]Q_N_?-STUM\N]Q!6LKZB9&X:,R%8V'/#(O2K#G]H'T]AJ8T&WK+;"&HK=3
MQ2+CIE*F248&!B24NZ]O0CG/OJ9--.GG1HT:-&C1HT:-&C1HT:-&C1HT:-&C
M1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:
E-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g799026g0404130120124.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g799026g0404130120124.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  P ( # 2(  A$! Q$!_\0
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,3_Y>(G5X=_UU/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g799026g0404130120377.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g799026g0404130120377.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  8 $ # 2(  A$! Q$!_\0
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MI7$\BZA%'=:;>HS9'SCS(F;KD=1]?<5['H[^&K6XO/"NEB&&:V0&XM5#!B&
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3\)-P#BBBFGM\B;6N_P#%^9__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
